Click here

axSpA: Axial spondyloarthritis; KOL: Key opinion leader; PsA: Plaque psoriasis; PSO: Psoriasis; Q2W: Every two weeks; RA: Rheumatoid arthritis.

C-VIEW was a 104-week (96 weeks plus 8-week safety follow-up) multicentre, open-label, phase 4 study. Eligible patients were adults who had active axSpA, HLA-B27 positivity and a history of recurrent acute anterior uveitis (≥2 acute anterior uveitis flares in total; ≥1 in the year prior to baseline). Patients received a loading dose of CIMZIA^® 400 mg at weeks 0, 2, and 4, followed by a maintenance dose of CIMZIA^® 200 mg every 2 weeks up to week 96. The primary efficacy endpoint was the acute anterior uveitis flare event rate during 96 weeks’ CIMZIA® vs. 2 years pre-baseline. Of 115 enrolled patients, 89 initiated CIMZIA^® and 83 patients completed the week 96 visit.⁵

1. CIMZIA^® Summary of Product Characteristics, July 2022. Last accessed 22/12/2022. Access the CIMZIA® SmPC

2. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228-233.

3. Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890-1896.

4. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018 May 12;20(6):35.

5. van der Horst-Bruinsma IE, van Bentum RE, Verbraak FD et al. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. Ther Adv Musculoskelet Dis. 2021 Mar 29;13:1759720X211003803.

CIMZIA^®, in combination with methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis in adults:

• For the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. CIMZIA^® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate
• For the treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs. 

CIMZIA^® has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.

CIMZIA^® is indicated for the treatment of adult patients with severe active axial spondyloarthritis comprising:​

• Adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs)​
• Adults with severe active axial spondyloarthritis without radiographic evidence of AS (nr-axSpA) but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have had an inadequate response to, or are intolerant to NSAIDs ​
  CIMZIA^®, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. CIMZIA^® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate​.

CIMZIA^® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy